Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 69.7%

Neg 69.7% Neu 0% Pos 0%

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.